<![CDATA[Current knowledge indicates that children infected with COVID‐19 are highly resilient and present with mild clinical symptoms. However, in May 2020 MIS-C, a Multisystem Inflammatory Syndrome in Children have been reported to be a dangerous childhood disease temporarily associated with COVID-19. D-dimer has been shown to be associated with severe and critical COVID-19, but little is known about the dominant clinical characteristics and laboratory results in Indonesian children, particularly Medan, Sumatra. This study aims to evaluate D-dimer and its clinical relationship to MIS-C with COVID-19 at RS Bunda Thamrin from the year 2020 to 2021. This research is a descriptive analytical study with a cross-sectional design. Clinical and laboratory parameters from medical records of confirmed COVID-19 children admitted to RS Bunda Thamrin were analyzed. 15 cases were included in this study. Categorical variables were compared using the Chi-square Test. Majority of COVID-19 cases occur in pediatric patients aged > 5 years (6.3%) followed by children aged < 5 years (35.7%). The median age is 8.8 + 5.83 years with a predominance in male patients (56.5%). Common presenting symptoms include respiratory manifestations such as cough (76.0%), rhinorrhoea (51.3%) and fever (39.0%). There is an association between D-dimer and the clinical characteristics p=0.02 (p<0.05) and D-dimer with laboratory results p=0.000 in CRP, neutrophils and lymphocytes and p=0.011 in thrombocytes (p<0.05).1 patient is suspected to have MIS-C in RS Bunda Thamrin Medan. D-dimer could be an early useful marker for predicting severe COVID-19 manifestations such as MIS-C.]]>
Copyrights © 2023
